Xilio Therapeutics, Inc. (XLO)
NASDAQ: XLO · Real-Time Price · USD
0.6967
+0.0066 (0.96%)
At close: Jul 25, 2025, 4:00 PM
0.6967
0.00 (0.00%)
After-hours: Jul 25, 2025, 4:21 PM EDT
Xilio Therapeutics Employees
Xilio Therapeutics had 64 employees as of December 31, 2024. The number of employees decreased by 9 or -12.33% compared to the previous year.
Employees
64
Change (1Y)
-9
Growth (1Y)
-12.33%
Revenue / Employee
$144,906
Profits / Employee
-$848,484
Market Cap
35.73M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 64 | -9 | -12.33% |
| Dec 31, 2023 | 73 | -16 | -17.98% |
| Dec 31, 2022 | 89 | 15 | 20.27% |
| Dec 31, 2021 | 74 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
XLO News
- 23 days ago - Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 weeks ago - Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors - GlobeNewsWire
- 7 weeks ago - Xilio Therapeutics Announces Closing of $50.0 Million Public Offering - GlobeNewsWire
- 7 weeks ago - Xilio Therapeutics Announces Pricing of $50.0 Million Public Offering - GlobeNewsWire
- 7 weeks ago - Xilio Therapeutics Announces Proposed Public Offering - GlobeNewsWire
- 7 weeks ago - Xilio Therapeutics Announces Updated Phase 2 Data for Vilastobart, a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer - GlobeNewsWire
- 2 months ago - Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial Results - GlobeNewsWire
- 3 months ago - Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire